Player FM 앱으로 오프라인으로 전환하세요!
Expert Discussions: Novel Agents Targeting Residual Inflammatory Risk in ASCVD and CKD
Manage episode 436382945 series 3242427
In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.
Episode outline:
- Colchicine: inhibition of NLRP3 inflammasome assembly/activation
- Canakinumab (anti–IL-1β monoclonal antibody)
- Ziltivekimab (anti–IL-6 monoclonal antibody)
- Other emerging targets/therapies
To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:
- CME-certified text module with animated pathophysiology video and faculty voice audio clips
- ClinicalThought commentaries
- Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD
- Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD
31 에피소드
Manage episode 436382945 series 3242427
In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.
Episode outline:
- Colchicine: inhibition of NLRP3 inflammasome assembly/activation
- Canakinumab (anti–IL-1β monoclonal antibody)
- Ziltivekimab (anti–IL-6 monoclonal antibody)
- Other emerging targets/therapies
To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:
- CME-certified text module with animated pathophysiology video and faculty voice audio clips
- ClinicalThought commentaries
- Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD
- Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD
31 에피소드
모든 에피소드
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.